Unique cancer vaccines target immunotherapy

Swiss-based AMAL Therapeutics is developing KISIMA, a unique protein-based immunization platform capable of producing single therapeutic vaccines for immunotherapy and beyond.

Like Comment
Page of
Go to the profile of Amal Therapeutics

Amal Therapeutics

AMAL Therapeutics SA is a spin-off from the University of Geneva active in cancer immunotherapy. AMAL has developed a unique protein-based immunization platform called KISIMA® providing activation signal to dendritic cells simultaneously to priming both helper and killer cells for various antigens and HLA restrictions. This first-in-class platform is offering the opportunity to develop standardized and indicationtailored active immunotherapies. The company’s lead product ATP128 is currently being developed for metastatic and advanced colorectal cancer.

No comments yet.